The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation to CK0804, an investigational regulatory T cell remedy developed by Cellenkos Inc., for the therapy of myelofibrosis, a uncommon blood most cancers, the corporate introduced. The designation is meant to help improvement of therapies for uncommon illnesses and comes as CK0804 continues to be evaluated in sufferers with myelofibrosis who haven’t responded to at the moment accessible remedies.
Myelofibrosis is characterised by scarring within the bone marrow, enlarged spleen and signs akin to anemia and fatigue that may considerably have an effect on high quality of life. Cellenkos is growing CK0804 as an allogeneic, off-the-shelf regulatory T cell remedy designed to scale back irritation and deal with disease-related adjustments within the bone marrow and different tissues.
Primary Information That Help the Findings
The orphan drug designation is supported by outcomes from a 13-patient scientific examine in myelofibrosis that had been introduced on the 67th Annual Assembly of the American Society of Hematology in December 2025. Sufferers enrolled within the examine had a median age of 68 years, with ages starting from 55 to 84 years, and had beforehand failed a median of two prior therapies, with a spread of 1 to 6.
Among the many sufferers who had been evaluable for response, 45% of 11 sufferers skilled a spleen quantity discount larger than 10%. As well as, 78% of 9 evaluable sufferers had a symptom burden discount larger than 50%. Enchancment in transfusion burden was reported in all three of three evaluable sufferers.
At a median follow-up of 195 days, which ranged from 41 to 809 days, 10 sufferers had been alive. Throughout this era, three sufferers proceeded to stem cell transplant, two switched to a unique class of remedy and the remaining sufferers continued their preliminary therapy with Jakafi (ruxolitinib).
Past scientific measures akin to spleen dimension and symptom burden, investigators noticed organic adjustments amongst sufferers who responded to CK0804. Responders demonstrated decreased circulating ranges of a number of inflammatory and disease-associated markers, together with remodeling progress issue beta 1, remodeling progress issue beta 2, fibroblast progress issue, platelet-derived progress issue and soluble CD40 ligand. Reductions in pathogenic monocytes had been additionally seen in each plasma and bone marrow, together with normalization of the bone marrow myeloid-to-erythroid ratio.
In accordance with the corporate, these findings counsel a possible disease-modifying impact of CK0804 in myelofibrosis.
What Are the Trial Particulars?
CK0804 consists of regulatory T cells that specific excessive ranges of the CXCR4 receptor, permitting the cells to preferentially dwelling to CXCL12, a ligand that’s overexpressed within the bone marrow and in websites of extramedullary hematopoiesis such because the spleen in myelofibrosis.
As soon as the cells attain goal tissues, CK0804 regulatory T cells work together with antigen-presenting cells and endure in vivo proliferation. Via this course of, the cells secrete interleukin-10, a suppressor cytokine, which is meant to scale back native and systemic irritation by a non–main histocompatibility complicated–restricted mechanism. The remedy can also be designed to manage platelet-derived progress issue–pushed pathways concerned in illness transforming.
CK0804 is derived from clinical-grade umbilical wire blood and manufactured utilizing Cellenkos’ proprietary CRANE course of. In accordance with the corporate, the remedy doesn’t require human leukocyte antigen matching, can evade innate immune surveillance and might be cryopreserved with a shelf lifetime of greater than two years whereas retaining viability and suppressor operate. The product is designed to be thawed and infused on demand by a peripheral intravenous line in an outpatient setting.
Dr. Simrit Parmar, founding father of Cellenkos, mentioned the designation helps additional improvement of the remedy for sufferers with myelofibrosis who’ve restricted choices. She famous that noticed will increase in interleukin-10 and reduces in remodeling progress issue beta ranges amongst responders, together with reductions in pathogenic monocytes, help the potential of CK0804 as a definite therapeutic strategy on this illness.
Security
The press launch didn’t report particular security occasions associated to CK0804. No treatment-related hostile occasions or security indicators had been detailed within the announcement. The corporate acknowledged that CK0804 is being superior into part 2 scientific trials for myelofibrosis as a part of its ongoing improvement program.
Reference
- “FDA Grants Orphan Drug Designation to Cellenkos’ CK0804 Treg Remedy for Remedy of Myelofibrosis.” Information Launch. Cellenkos. Jan 6, 2026.
Editor’s be aware: This text is for informational functions solely and isn’t an alternative to skilled medical recommendation, as your personal expertise might be distinctive. Use this text to information discussions along with your oncologist. Content material was generated with AI, reviewed by a human editor, however not independently verified by a medical skilled.
For extra information on most cancers updates, analysis and schooling, don’t neglect to
